Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC

Summary

Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer often diagnosed at advanced stages, with limited treatment options and poor prognosis. Oxidative stress, inflammation, and dysregulated signaling pathways contribute to tumor progression, metastasis, and chemotherapy resistance. Alpha-lipoic acid (ALA), a potent antioxidant with anti-inflammatory properties, has shown promise in preclinical and early clinical studies by reducing oxidative stress, enhancing chemotherapy efficacy, and improving immune response. The aim of this study is to evaluate the clinical effect and safety of oral ALA (600 mg daily) in combination with standard platinum-based chemotherapy in patients with advanced non-resectable Stage III or IV NSCLC. Primary outcomes include clinical benefit and tumor response, while secondary outcomes include 1-year progression-free survival, 1-year overall survival, chemotherapy toxicity, and quality of life.

Timeline

Start

2026-04-20

Primary completion

2027-01-01

Completion

2027-04-20

Publications

• Background 1. Clark SB, Alsubait S. Non-small cell lung cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. 2. El Agamawi AY, Tarrad MM, et al. Clinical and pathological characteristics of patients with non-small cell lung cancer: retrospective study. Al-Azhar Int Med J. 2025 Apr;6(4):Article 5. doi:10.58675/2682-339X.2891. 3. Molina JR, Yang P, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-594. doi:10.4065/83.5.584. 4. Lababede O, Meziane MA. The eighth edition of TNM staging of lung cancer: reference chart and diagrams. Oncologist. 2018 Jul;23(7):844-848. doi:10.1634/theoncologist.2017-0659. 5. Jeon H, Wang S, et al. Update 2025: management of non-small cell lung cancer. Lung. 2025 Mar 25;203(1):53. doi:10.1007/s00408-025-00801-x. 6. Saleem N, Habib A, et al. Phytocompounds as promising weapons against lung cancer: a review. Phytopharm Commun. 2024;4:57-68. doi:10.55627/ppc.004.001.0546. 7. Yan S, Lu J, et al. The multifaceted role of alpha-lipoic acid in cancer prevention, occurrence, and treatment. Antioxidants. 2024 Aug;13(8):897. doi:10.3390/antiox13080897. 8. Ferrigno D, Buccheri G, et al. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer. Lung Cancer. 2003 Sep;41(3):311-320. doi:10.1016/s0169-5002(03)00232-0. 9. Pingali U, Kammila S, et al. Effect of alpha-lipoic acid on neuropathic symptoms in diabetic neuropathy patients. Cureus. 2024 Sep 27;16(9):e70299. doi:10.7759/cureus.70299. 10. Petrella F, Rizzo S, et al. Stage III non-small-cell lung cancer: an overview of treatment options. Curr Oncol. 2023 Mar;30(3):3160-3175. doi:10.3390/curroncol30030239. 11. Nguyen H, Pellegrini MV, et al. Alpha-lipoic acid. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 12. Fogacci F, Rizzo M, et al. Safety evaluation of alpha-lipoic acid supplementation: a systematic review and meta-analysis. Antioxid

Drugs

Indications